NantHealth and Allscripts are teaming-up to develop precision medicine solutions directly to the point of care. The two companies plan to introduce an integrated, evidence-based, personalized approach to healthcare solutions that includes actionable clinical data, enabling physicians to make informed decisions from complex genomic and proteomic analysis.

“Our goal is to enable physicians to make better, more informed decisions, provide best-in-class patient care and monitor the effectiveness and progress of treatment, using real-time clinical and pan-omic data never before available,” said Dr. Patrick Soon-Shiong, founder and CEO of NantHealth.

The ability to make evidence-based clinical decisions by using specifically matched cancer protocols and drugs can improve patient outcomes.The ability to make evidence-based clinical decisions by using specifically matched cancer protocols and drugs can improve patient outcomes. The new technology allows treatments tailored to individual’s unique DNA, RNA and proteomic profile, and integrated with the patient’s holistic clinical picture.

Together, physicians and patients will have the tools to stay engaged and active and provide necessary intervention as early as possible. Leveraging innovations in patient engagement, care coordination and disease management, NantHealth and Allscripts are creating the first fully comprehensive and integrated platform that will provide a transformation to the coordination and delivery of cancer care.

“We’re working with NantHealth to create a game-changing platform for coordinated cancer care,” Allscripts CEO Paul M. Black said. “Integrated patient information – from the molecular level and from the entire continuum of care – is a powerful tool to improve health care.”